Trials / Completed
CompletedNCT05860530
Bioequivalence Study of Two Olaparib Tablets in Patients With Cancers
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study aimed to evaluate the pharmacokinetic characteristics and bioequivalence of two olaparib tablets in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | The test olaparib tablet (T) | The test olaparib tablet (Qilu Pharmaceutical Co., Ltd., Jinan, China) 300mg, every 12 hours |
| DRUG | The reference olaparib tablet (R) | The reference olaparib tablet (Lynparza®; AstraZeneca PLC, Cambridge, England, UK) 300mg, every 12 hours |
Timeline
- Start date
- 2021-05-10
- Primary completion
- 2021-09-08
- Completion
- 2021-09-08
- First posted
- 2023-05-16
- Last updated
- 2023-06-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05860530. Inclusion in this directory is not an endorsement.